Pembrolizumab plus Pemetrexed and Platinum in Metastatic Non-Squamous Non-Small Cell Lung Cancer: A Real-Life Study at a Portuguese Centre
First-line therapy for metastatic non-small-cell lung cancer without targetable mutations is platinum-based chemotherapy plus pembrolizumab if programmed death ligand 1 is < 50%. The aim of this real-life retrospective study is to assess the efficacy and safety of this therapy. This retrospectiv...
Saved in:
Main Authors: | Maria João Santos, Filipa Ferro, Andrea Machado, Ana Sofia Vilariça, Direndra Hasmucrai, Paula Alves |
---|---|
Format: | Article |
Language: | English |
Published: |
Ordem dos Médicos
2025-02-01
|
Series: | Acta Médica Portuguesa |
Subjects: | |
Online Access: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/22126 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50%
by: Yoshihito Kogure, MD, PhD, et al.
Published: (2025-03-01) -
Methods for preliminary determination of pemetrexed in macromolecular drug-carrier systems
by: Ciekot Jarosław, et al.
Published: (2016-03-01) -
Cytotoxic mechanisms of pemetrexed and HDAC inhibition in non-small cell lung cancer cells involving ribonucleotides in DNA
by: Tobias Solli Iveland, et al.
Published: (2025-01-01) -
Maxillary osteonecrosis linked to Pembrolizumab therapy: a case report
by: Gosselin-Rousselle Louise, et al.
Published: (2024-01-01) -
Pembrolizumab for the Treatment of Locally Advanced Cutaneous Squamous Cell Carcinoma: Patient Selection and Special Considerations
by: Stewart M, et al.
Published: (2025-02-01)